A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

New England Journal of Medicine

Volumn 376, Issue 4, 2017, Pages 330-341

  Regules, J A ^a   Beigel, J H ^c   Paolino, K M ^a   Voell, J ^e   Castellano, A R ^a   Hu, Z ^e   Munoz P ^e   Moon, J E ^a   Ruck, R C ^a   Bennett, J W ^a   Twomey, P S ^a   Gutierrez R L ^b   Remich, S A ^a   Hack, H R ^a   Wisniewski, M L ^d   Josleyn, M D ^d   Kwilas, S A ^d   Van Deusen, N ^d   Mbaya, O T ^e   Zhou, Y ^e   Stanley, D A ^e   Jing, W ^c   Smith, K S ^d   Shi, M ^a   Ledgerwood, J E ^e   Graham, B S ^e   Sullivan, N J ^e   Jagodzinski, L L ^a   Peel, S A ^a   Alimonti, J B ^f   Hooper, J W ^d   Silvera, P M ^d   Martin, B K ^g   Monath, T P ^g   Ramsey, W J ^g   Link, C J ^g   Lane, H C ^e   Michael, N L ^a   Davey, R T ^e   Thomas, S J ^a   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g NEWLINK GENETICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; PLACEBO; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS ZAIRE EBOLAVIRUS VACCINE; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; LIVE VACCINE; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ABDOMINAL PAIN; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; BLOODY DIARRHEA; CERVICAL LYMPHADENOPATHY; CHILL; COLITIS; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; INFORMED CONSENT; INJECTION SITE PAIN; LYMPHOCYTOPENIA; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; RASH; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; VACCINATION; ZAIRE EBOLAVIRUS; ZAIRE KIKWIT EBOLAVIRUS; BLOOD; CLINICAL TRIAL; EBOLAVIRUS; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; VESICULAR STOMATITIS INDIANA VIRUS; VIREMIA;

ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SEROCONVERSION; VACCINES, ATTENUATED; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIREMIA;

EID: 85011081815     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1414216     Document Type: Article

References (27)

1. Ebola situation report - 30 March 2016. Geneva: World Health Organization (http://apps .who .int/ ebola/ current-situation/ ebola-situation-report-30-march-2016).
2. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014; 13: 521-31.
3. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa1410863.
4. Ewer K, Rampling T, Venkatraman N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 2016; 374: 1635-46.
5. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386: 857-66.
6. Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 2000; 74: 10194-201.
7. Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in nonhuman primates. Virology 2007; 360: 36-49.
8. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virusbased Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4(11): e1000225.
9. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204: Suppl 3: S1075-S1081.
10. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virusbased vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008; 26: 6894-900.
11. Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One 2009; 4(5): e5547.
12. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, openlabel, cluster-randomised trial (Ebola Ca Suffit!). Lancet 2016 December 23 (Epub ahead of print).
13. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78: 5458-65.
14. Kugelman JR, Sanchez-Lockhart M, Andersen KG, et al. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. MBio 2015; 6: e02227-14.
15. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Silver Spring, MD: Food and Drug Administration, September 2007 (http:// www .fda .gov/ BiologicsBloodVaccines/ GuidanceComplianceRegulatory Information/ Guidances/ Vaccines/ ucm074775 .htm).
16. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3(6): e177.
17. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016; 374: 1647-60.
18. Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebocontrolled phase 1/2 trial. Lancet Infect Dis 2015; 15: 1156-66.
19. Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular stomatitis virusbased vaccines for prophylaxis and treatment of filovirus infections. J Bioterr Biodef 2011. Special Issue 1 (http://www .omicsonline .org/ 2157-2526/ 2157-2526-S1-004 .digital/ 2157-2526-S1-004 .html).
20. Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012; 6(3): e1567.
21. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 2010; 6(5): e1000904.
22. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 2013; 110: 1893-8.
23. Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012; 4: 158ra146.
24. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11: 786-90.
25. Hooper JW. Neutralization assays. In: Immunology of protection from Ebola virus infection. NIH VideoCasting and Podcasting (http://videocast .nih .gov/ launch .asp?18779).
26. Feldmann H, Jones SM, Daddario- DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3(1): e2.
27. Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014; 32: 5722-9.